13th International Conference on Myasthenia Gravis and Related Disorders

第十三届重症肌无力及相关疾病国际会议

• 批准号: 9331903
• 负责人: Melanie Brickman Borchard
• 金额: $ 1.5万
• 依托单位: NEW YORK ACADEMY OF SCIENCES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-15 至 2018-05-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9331903
• 关键词: Academia; Academy; Address; Advocate; Americas; Animal Model; Area; Autoimmune Diseases; Autoimmune Process; Autoimmunity; Award; Basic Science; Caring; Case Study; Child; Chronic Disease; Clinic; Clinical; Clinical Investigator; Clinical Trials; Collaborations; Communication; Communities; Congresses; Data; Development; Diagnosis; Disabled Persons; Disease; Educational workshop; Emerging Technologies; Etiology; Event; Faculty; Family; Fatigue; Fellowship; Female; Fostering; Foundations; Future; Genomics; Goals; Government; Guidelines; Health; Immunotherapy; Industry; International; Internet; Knowledge; Life Expectancy; Medical; Mentors; Minority; Mission; Modernization; Muscle Weakness; Myasthenia; Myasthenia Gravis; National Institute of Neurological Disorders and Stroke; Neurobiology; Neurologic; Neuromuscular Diseases; Neuromuscular Junction; New York; New York City; Nicotinic Receptors; Oral; Participant; Pathogenesis; Patient Care; Patient-Focused Outcomes; Patients; Pharmacologic Substance; Phenotype; Physicians; Physiological; Prize; Process; Public Health; Publications; Publishing; Quality of life; Research; Research Personnel; Science; Scientist; Serological; Structure; Syndrome; Techniques; Technology; Therapeutic; Translating; Translations; Travel; Treatment Protocols; Underrepresented Minority; Update; Woman; aging population; career; clinical care; clinical development; disability; discount; improved; innovation; meetings; minority investigator; mortality; multidisciplinary; nervous system disorder; neuromuscular; neuromuscular function; posters; programs; racial and ethnic; racial minority; receptor structure function; repository; research and development; response; screening; standard care; symposium; treatment response

13th International Conference on Myasthenia Gravis and Related Disorders PROJECT SUMMARY / ABSTRACT The treatment for myasthenia gravis (MG) — a rare, acquired autoimmune syndrome resulting in severe muscle weakness, significant disability, and decreased life expectancy — has improved dramatically in the last several decades. However, many knowledge gaps still remain to improving MG patient outcomes including the understanding the origin of MG, identifying the factors that contribute to chronic disease, and finding a way to cure the disease. To address these unmet needs, the New York Academy of Sciences and the Myasthenia Gravis Foundation of America will convene the 3-day 13th International Conference on Myasthenia Gravis and Related Disorders on May 15 – 17, 2017, in New York City, NY. This conference will convene approximately 300 attendees — including basic scientists and clinical investigators in academia, industry, and government; physicians; pharmaceutical strategists; and patient advocates — in an effort to address these aforementioned knowledge gaps. Conference sessions will combine basic, translational, and clinical researchers and will feature a unique format of short, focused talks centered on critical open research questions, with the 13 plenary sessions focusing on: structure and function of the neuromuscular junction, congenital syndromes, serological phenotypes, mechanisms of autoimmunity, recent clinical developments, animal models of neuromuscular disease, MG treatment updates, and global MG treatment guidelines. The five central aims of this program are to: (i) provide a forum for basic, translational, and clinical researchers from academia and industry to present and discuss the most up-to-date findings in MG research; (ii) explore and encourage multidisciplinary and multi-sector collaborations to enhance investigative approaches into MG and related autoimmune and neuromuscular disorders; (iii) review current MG therapeutic options, ongoing clinical trials, and challenges and limitations faced in the clinic; (iv) identify knowledge gaps and future directions of research required for further breakthroughs; and (v) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations, travel fellowships, career mentoring activities, and discounted registration. The conference goals align well with the mission of the National Institute of Neurological Disorders and Stroke (NINDS) to support the advancement of new knowledge on neurological disorders. In addition, the NINDS’ specific goal of disseminating information about scientific discoveries and their implications for neurological health will be met via a live simulcast broadcast of the meeting and the publication of a post-conference, enduring, open-access, Section 508-compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the meeting to the global research and medical communities. Only through cross-field collaborative research envisioned as a result of this conference can we fully guide research forward in the field, particularly with respect to potential innovative therapeutic approaches.

第十三届重症肌无力及相关疾病国际会议 项目概要/摘要 重症肌无力 (MG) 的治疗——一种罕见的获得性自身免疫综合征，可导致严重的肌肉萎缩 虚弱、严重残疾和预期寿命下降——在过去几年中得到了显着改善 几十年。然而，在改善 MG 患者预后方面仍然存在许多知识差距，包括 了解 MG 的起源，确定导致慢性病的因素，并找到治疗方法 治愈疾病的方法。为了解决这些未满足的需求，纽约科学院和 美国重症肌无力基金会将召开为期3天的第13届国际重症肌无力会议 重症肌无力及相关疾病于 2017 年 5 月 15 日至 17 日在纽约州纽约市举行。本次大会将 召集大约 300 名与会者——包括学术界的基础科学家和临床研究人员， 工业界和政府；医生；医药策略师；和患者倡导者——努力 解决上述知识差距。会议会议将结合基础、翻译和 临床研究人员将采用一种独特的形式，以关键的开放研究为中心，进行简短而集中的演讲 问题，13次全体会议重点讨论：神经肌肉接头的结构和功能， 先天性综合征、血清学表型、自身免疫机制、近期临床 进展、神经肌肉疾病动物模型、MG 治疗更新和全球 MG 治疗指南。该计划的五个中心目标是：(i) 为基础、转化、 来自学术界和工业界的临床研究人员展示并讨论最新的研究结果 MG研究； (ii) 探索和鼓励多学科、多部门合作，以加强 重症肌无力及相关自身免疫和神经肌肉疾病的研究方法； (iii) 审查当前的 MG 治疗选择、正在进行的临床试验以及临床面临的挑战和限制； (四) 确定 知识差距和进一步突破所需的未来研究方向； (v) 展示和 通过短期鼓励早期职业、女性和代表性不足的少数族裔调查员的参与 讲座、海报展示、旅行奖学金、职业指导活动和折扣注册。这 会议目标与国家神经疾病和中风研究所 (NINDS) 的使命高度契合 支持神经系统疾病新知识的进步。此外，NINDS 的具体目标 传播有关科学发现及其对神经健康的影响的信息将得到满足 通过会议现场联播和会后出版一份持久的、开放获取的、 纽约科学院年鉴中符合第 508 条规定的会议报告，该报告将分发 会议上向全球研究和医学界交流的科学知识和思想。 只有通过本次会议所设想的跨领域合作研究，我们才能充分指导 该领域的研究进展，特别是在潜在的创新治疗方法方面。